肾上腺皮质癌市场 - 全球和区域分析：区域和国家分析 - 分析和预测（2025-2035）

全球肾上腺皮质癌 (ACC) 市场目前正处于其生命週期的成长阶段。

儘管 ACC 仍然是一种罕见疾病和难以治疗的癌症，但诊断技术和治疗方案的进步预计将推动市场成长。此外，增加研究投入和临床试验也正在推动市场发展，加速新治疗方法的开发。然而，由于发病率相对较低，导致患者数量有限且治疗方法规模化采用缓慢，市场仍受到限制。儘管存在这些挑战，但由于对个人化医疗的日益关注，市场预计仍将继续增长。随着更有针对性的治疗方法和改进的治疗通讯协定的推出，预计未来几年市场将进一步成熟和扩大。

影响

• 预计在 2025-2035 年预测期内，对肾上腺皮质癌治疗的需求不断增长将支持全球肾上腺皮质癌市场的成长。
• 由于诊断技术的进步、创新治疗方法的市场推出以及患者和医疗保健提供者意识的提高，全球肾上腺皮质癌市场预计将显着增长。

近期动态

• 资金筹措2025 年 4 月，Cytovation 获得 600 万美元用于 CY-101 治疗肾上腺皮质癌的临床试验。
• 伙伴关係2025 年 1 月，英国癌症研究中心、Cytovation 和挪威癌症协会签署了一项协议，将 Cytovation 的主要资产 CY-101 推进到针对肾上腺皮质癌患者的跨国 2 期临床试验。

驱动程式

• 肾上腺皮质癌盛行率不断上升
• 治疗方案的持续进步
• 改进的诊断技术

限制因素

• 医疗费用高昂

产品/创新策略：全球肾上腺皮质癌市场的产品发布和创新专注于推进治疗方案以改善患者护理。这些创新旨在提高治疗效果并简化疾病的检测和管理。 Cytovation 等市场关键参与企业正在参与开发肾上腺皮质癌的治疗方法。

竞争策略：主要关注全球肾上腺皮质癌市场领导的公司正在不断致力于透过创新治疗方法更新产品系列以保持竞争力。它对主要参与企业进行了详细的竞争基准化分析，并提供了这些公司在产品供应、市场占有率和创新方面的比较情况的见解。透过这种基准化分析，读者可以清楚地了解市场格局和主要企业的地位。此外，包括伙伴关係、协议和联盟在内的综合竞争策略可协助读者发现市场中尚未开发的商机。

本报告研究了全球肾上腺腺癌市场，并概述了市场以及区域趋势和公司概况。

目录

执行摘要

第一章全球肾上腺皮质癌市场概述

• 产业展望
  • 市场概况与生态系统
  • 市场趋势
  • 肾上腺皮质癌流行病学分析
  • 临床试验
  • 监管状况/合规性
• 市场动态
  • 影响分析
  • 市场驱动因素
  • 市场限制
  • 市场机会

2. 全球肾上腺皮质癌市场，按地区划分，百万美元，2023-2035 年

• 北美洲
• 欧洲
• 亚太地区

3. 全球肾上腺皮质癌市场竞争基准化分析与公司概况

• 竞争格局
  • 各公司主要策略及发展
  • 关键进展
• 公司简介
  • HRA Pharma
  • Cytovation
  • Exelixis, Inc.
  • Bristol-Myers Squibb

第四章调查方法

Market Lifecycle Stage

The global adrenocortical carcinoma market is currently in the growth stage of its lifecycle. While ACC remains a rare disease and challenging cancer to treat, advancements in diagnostic technologies and treatment options are expected to drive the growth of the market. The market is also benefiting from increased research investments and clinical trials, which are accelerating the development of new therapies. However, the market is still limited by the relatively low incidence of the disease, which restricts the patient pool and slows large-scale adoption of treatments. Despite these challenges, the growing focus on personalized medicine is expected to drive continued growth in the market. As more targeted therapies and improved treatment protocols are introduced, the market is poised for further maturation and expansion in the coming years.

Impact

• Increasing demand for adrenocortical carcinoma therapies is anticipated to support the growth of the global adrenocortical carcinoma market during the forecast period 2025-2035.
• The global adrenocortical carcinoma market is expected to grow at a significant rate due to advancements in diagnostic technologies, the development of innovative therapies, and increasing awareness among patients and healthcare providers.

Recent Developments

• Fundings: In April 2025, Cytovation secured $6 million for the clinical trial of CY-101 aimed at treating adrenocortical carcinoma.
• Partnerships: In January 2025, Cancer Research UK, Cytovation, and the Norwegian Cancer Society signed an agreement to advance Cytovation's lead asset, CY-101, into a multi-national Phase 2 clinical trial for patients with adrenocortical carcinoma.

Demand - Drivers and Limitations

Drivers:

• Increasing Prevalence of Adrenocortical carcinoma
• Continuous Advancements in Treatment Options
• Improved Diagnostic Technologies

Limitations:

• High Treatment Costs

How Can This Report Add Value to an Organization?

Product/Innovation Strategy: Product launches and innovations in the global adrenocortical carcinoma market are focused on advancing treatment options to improve patient care. These innovations aim to enhance the efficacy of therapies and streamline the detection and management of the disease. Key players in the market, such as Cytovation, have been involved in the development of therapies for adrenocortical carcinoma.

Competitive Strategy: Enterprises led by market leaders in the global adrenocortical carcinoma market are continuously working on updating their product portfolios with innovative treatments to maintain competitiveness. A detailed competitive benchmarking of the key players has been conducted, providing insights into how these companies compare in terms of product offerings, market share, and innovation. This benchmarking provides readers with a clear understanding of the market landscape and the positions of the leading players. Additionally, comprehensive competitive strategies, such as partnerships, agreements, and collaborations, will help readers identify untapped revenue opportunities in the market.

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts and by analyzing company coverage, product portfolio, and market penetration.

Some of the prominent names established in this market are:

• HRA Pharma
• Cytovation
• Exelixis, Inc.
• Bristol-Myers Squibb

Table of Contents

Executive Summary

Scope of Study

1. Global Adrenocortical Carcinoma Market Overview

• 1.1 Industry Outlook
  • 1.1.1 Market Overview and Ecosystem
  • 1.1.2 Market Trends
  • 1.1.3 Epidemiological Analysis of Adrenocortical Carcinoma
    • 1.1.3.1 By Region
  • 1.1.4 Clinical Trials
    • 1.1.4.1 By Phase
    • 1.1.4.2 By Sponsor Type
  • 1.1.5 Regulatory Landscape / Compliance
    • 1.1.5.1 Legal Requirement and Framework in the U.S.
    • 1.1.5.2 Legal Requirement and Framework in the E.U.
    • 1.1.5.3 Legal Requirement and Framework in Asia-Pacific
• 1.2 Market Dynamics
  • 1.2.1 Impact Analysis
  • 1.2.2 Market Drivers
  • 1.2.3 Market Restraints
  • 1.2.4 Market Opportunities

2. Global Adrenocortical Carcinoma Market, By Region, $Million, 2023-2035

• 2.1 North America
  • 2.1.1 Market Dynamics
  • 2.1.2 Market Size and Forecast
    • 2.1.2.1 North America Adrenocortical Carcinoma Market (by Country)
      • 2.1.2.1.1 U.S.
• 2.2 Europe
  • 2.2.1 Market Dynamics
  • 2.2.2 Market Size and Forecast
    • 2.2.2.1 Europe Adrenocortical Carcinoma Market (by Country)
      • 2.2.2.1.1 U.K.
      • 2.2.2.1.2 Germany
      • 2.2.2.1.3 France
      • 2.2.2.1.4 Italy
      • 2.2.2.1.5 Spain
• 2.3 Asia-Pacific
  • 2.3.1 Market Dynamics
  • 2.3.2 Market Size and Forecast
    • 2.3.2.1 Asia-Pacific Adrenocortical Carcinoma Market (by Country)
      • 2.3.2.1.1 Japan

3. Global Adrenocortical Carcinoma Market - Competitive Benchmarking and Company Profiles

• 3.1 Competitive Landscape
  • 3.1.1 Key Strategies and Developments by Company
    • 3.1.1.1 Funding Activities
    • 3.1.1.2 Mergers and Acquisitions
    • 3.1.1.3 Regulatory Approvals
    • 3.1.1.4 Partnerships, Collaborations, and Business Expansions
  • 3.1.2 Key Developments Analysis
• 3.2 Company Profiles
  • 3.2.1 HRA Pharma
    • 3.2.1.1 Company Overview
    • 3.2.1.2 Product Portfolio
    • 3.2.1.3 Target Customers/End Users
    • 3.2.1.4 Analyst View
  • 3.2.2 Cytovation
    • 3.2.2.1 Company Overview
    • 3.2.2.2 Product Portfolio
    • 3.2.2.3 Target Customers/End Users
    • 3.2.2.4 Analyst View
  • 3.2.3 Exelixis, Inc.
    • 3.2.3.1 Company Overview
    • 3.2.3.2 Product Portfolio
    • 3.2.3.3 Target Customers/End Users
    • 3.2.3.4 Analyst View
  • 3.2.4 Bristol-Myers Squibb
    • 3.2.4.1 Company Overview
    • 3.2.4.2 Product Portfolio
    • 3.2.4.3 Target Customers/End Users
    • 3.2.4.4 Analyst View

4. Research Methodology

List of Figures

• Figure: Global Adrenocortical Carcinoma Market, Market Overview
• Figure: Global Adrenocortical Carcinoma Market, Epidemiological Analysis, U.S.
• Figure: Global Adrenocortical Carcinoma Market Coverage
• Figure: Global Adrenocortical Carcinoma Market Key Trends, Impact Analysis, 2023-2035
• Figure: Global Adrenocortical Carcinoma Market, Competitive Landscape, January 2022-April 2025

List of Tables

• Table Global Adrenocortical Carcinoma Market, Regulatory Scenario
• Table Global Adrenocortical Carcinoma Market Dynamics, Impact Analysis